Jan 19, 2017

Shareholder Update January 2017

In this issue:

›› Enrolment completed for phase 3 program: VivaGel^® BV for prevention of recurrence

›› VivaGel^® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel^® condom approved in Canada; licensed in China and Iran

›› New DEP^® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP^® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP^® cabazitaxel shows no neutropenia

›› DEP^® irinotecan internal program shows superior performance

Download: Shareholder January 2017 (pdf file, 751kb)

 This contains certain forward-looking statements.